Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

BACKGROUND: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W. N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2017
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5322633/
https://ncbi.nlm.nih.gov/pubmed/28228106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0417-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker